MacTel Project 2021 Update
LOWY MEDICAL RESEARCH INSTITUTE – LMRI This past year has surely been an interesting and challenging one. We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges presented by the pandemic, all our investigators and clinical sites are to be commended for continuing… View Article
CNTF Phase 3 Trial Enrollment Complete
September 21, 2020 In a collaboration with Neurotech Pharmaceuticals, the Lowy Medical Research Institute is conducting a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center trial, with clinical sites in the United States, Europe, and Australia. The clinical trial tests whether CNTF, a small… View Article
CNTF Clinical Trials: COVID-19 Update
March 24, 2020 The rapid spread of COVID-19 has disrupted many standard clinical operations, including the LMRI/Neurotech Phase 1, 2, and 3 clinical trials testing CNTF in MacTel. If you have questions regarding upcoming appointments or other study-related questions and are having trouble reaching the study team, please use our contact page and we will assist… View Article
Phase 3 Trial Currently Enrolling MacTel Patients
In a collaboration with Neurotech Pharmaceuticals, the Lowy Medical Research Institute is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center trial, with clinical sites in the United States, Europe, and Australia. How do I Participate? You may contact a clinical site… View Article
The Latest MacTel Research: What does it mean for patients?
Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2. The article, “Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy,” was published online by the New England Journal of Medicine on September 11, 2019.1 The findings… View Article
Lowy Medical Research Institute scientists find cause of debilitating eye disease
15-year effort points to treatments to help MacTel patients and offers potential new insights into other eye diseases LA JOLLA, CA–September 11, 2019– Scientists at the Lowy Medical Research Institute (LMRI) have discovered one cause of a progressive, debilitating eye disease called macular telangiectasia type 2 (MacTel). The work, using genetic, clinical and biochemical studies… View Article
Results of NT-501 Phase 2 Study Published
January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal of the American Academy of Ophthalmology, Ophthalmology1. The study, a Phase 2 multi-center randomized clinical trial, tested… View Article
2018 MacTel Project Annual Summary
The Lowy Medical Research Institute would like to announce the latest MacTel Project Newsletter, which contains important updates on the Natural History Observation and Registry (NHOR) Study, Clinical Trials, and MacTel Projects.
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia
Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macular Telangiectasia type 2 (MacTel). The multicenter, randomized clinical trial demonstrated a statistically significant reduction in the progressive loss of photoreceptors in treated versus untreated eyes. NT-501 utilizes the Company’s proprietary Encapsulated Cell Therapy (ECT) platform that can be customized to deliver specific therapeutic molecules to the back of the eye for retinal disease.
LMRI Scientists Selected to Participate in Biocom’s “Taking Art to the Cellular Level” Exhibit
Two scientists affiliated with the Lowy Medical Research Institute, Dr. Peter Westenskow and Dr. Michael Dorrell, were selected to participate in a public exhibit that showcased the artistic side of science. Dr. Westenskow exhibited an image of the architecture of the retina, taken by electron microscopy. The image was taken in collaboration with Dr. Malcom Wood at The Scripps Research Institute.